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Abstract
The C1D gene is expressed in a broad spectrum of mammalian cells and tissues but its product
induces apoptotic cell death when exceeding a critical level. Critical levels are achieved in a fraction
of cells by transient transfection with EGFP-tagged C1D expression constructs. However,
transfected cells expressing sub-critical levels of C1D(EGFP) escape apoptotic cell death by
activation of a proteasome-mediated rescue mechanism. Inhibition of the proteasome-dependent
degradation of the C1D(EGFP) protein results in a parallel increase of the intracellular C1D level
and in the fraction of apoptotic cells.
Background
The C1D gene encodes a conserved DNA-binding protein
[1] which is expressed in all eukaryotic cells and tissues
tested [2]. However, the physiological level of this protein
must be tightly regulated because additional ectopic ex-
pression induces apoptotic cell death [2]. Previous studies
showed that the C1D protein can serve as a DNA end-in-
dependent activator of DNA-PK [3] and that its overflow
is paralleled by increased p21Cip1(Waf1) levels [2]. Ac-
cordingly, the C1D protein represents a cryptic activator
of apoptosis, and its over-expression could be applied to
induce apoptosis in non-desired cells, e.g. in tumor cells.
Accordingly, approaches resulting in increased levels of
this protein are of interest. This study shows that the vec-
tor-based overflow of the C1D protein can be significantly
enhanced by inhibition of the proteasome-dependent
degradation system.
Results
Threshold level for C1D-induced apoptosis
Ectopical expression of the enhanced green fluorescent
protein (EGFP) in Ehrlich ascites cells does not cause any
significant impairment of cellular parameters, e.g. viabili-
ty and growth [2]. Transiently transfected cells exhibit var-
iable fluorescence intensities over a broad range and the
level of expression observed in individual transfectants
appears to be primarily dependent on the introduced
plasmid copies per cell. Moreover, the fraction of cells ex-
pressing EGFP is high and the level of expressed EGFP re-
mains high over prolonged observation periods, e.g. 120
hours (Fig. 1). The persisting high level in transfectants in-
dicates that the innoxious EGFP does not stimulate any
specific degradation mechanism. A moderate decline in
the number of fluorescent cells at about 48 hours post
transfection reflects the expected proliferation-dependent
dilution of EGFP-encoding plasmids in transiently trans-
fected cells.
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In contrast, a bi-modal distribution of fluorescence inten-
sities is observed following transfection with the CMV
promoter-driven construct inducing ectopical expression
of the C1D(EGFP) fusion protein. A fraction of transfect-
ants exhibits extremely high fluorescence (Fig. 2) while a
larger fraction of cells shows significant but much weaker
fluorescence (Fig. 3). In highly fluorescent cells the fusion
protein accumulates in dense intranuclear spots while
plasma vacuolization, membrane blebbing, nuclear seg-
mentation, and cell lysis are further steps in cell death. The
size of this cell fraction depends on the plasmid concen-
tration applied and on the promoter strength of the ex-
pression construct, e.g. the SV40 promoter-driven
expression construct pJ3-C1D(EGFP) results in general-
ly smaller fractions of apoptotic cells which indicates that
a critical level of C1D(EGFP) is required for the produc-
tion of Figure 2-type cells. The fraction of transfectants ex-
hibiting significantly weaker fluorescence (Fig. 3) is
generally larger, and cells of this fraction show no symp-
toms of apoptotic cell death. Importantly, 120 hours post
transfection all cells of the culture are devoid of
C1D(EGFP)-dependent fluorescence while cells transfect-
ed with the plasmid encoding only EGFP show still high
fluorescence at this time (Fig. 1).
The complete disappearance of fluorecent cells at 120
hours post transfection is only partly due to cell death of
those cells exhibiting the morphologies shown in Fig. 2
because the drop in the number of fluorescent cells is not
accompanied by an adequate drop in the total number of
cells (not shown). Accordingly, cells expressing subcritical
levels escape apoptotic cell death because they appear to
be capable to induce a rescue mechanism which prevents
overcritical C1D(EGFP) levels. Obviously, this mecha-
nism is fully induced at 120 hours post transfection (Fig.
1). At this time C1D(EGFP) degradation overrides expres-
sion of this protein resulting in normally growing cells de-
void of fluorescence.
Figure 1
Persistence of ectopically expressed EGFP, and instability of
C1D(EGFP). Percentage of cells exhibiting fluorescence fol-
lowing transient transfection of cultured EAT cells side by
side with 20 g pcDNA3-EGFP or with pcDNA3-
C1D(EGFP), respectively. The fraction of cells with significant
EGFP-depending fluorescence remains high over the entire
observation period (24–120 hours post transfection) while
the number of cells with C1D(EGFP)-depending fluorescence
is lower at 24 hours, and declines rapidly at 72–120 hours
post transfection.
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Figure 2
Transfected and apoptotic cells. A fraction of cells exhibits
extremely high C1D(EGFP)-dependent fluorescence when
transfected with pcDNA3-C1D(EGFP). Cells belonging to
this fraction can be distinguished by morphology and short
exposure times required to capture 510 nm fluorescence
mode images (about 100 milliseconds). Upper row: phase
contrast mode; second row: DNA-specific fluorescence (456
nm); third row C1D(EGFP)-specific fluorescence (510 nm).
Bars represent 10 m.Cancer Cell International 2002, 2 http://www.cancerci.com/content/2/1/12
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These results are best explained by a point-of-no-return
mechanism in C1D-dependent apoptosis signalling.
Overcritical C1D protein levels are expectedly achieved in
those cells with an initially high number of plasmid cop-
ies per cell. In this case, the C1D(EGFP) threshold level is
presumptively exceeded and apoptosis is inevitably in-
duced while cells with a lower number of plasmid copies
per cell expressing only subcritical C1D(EGFP) levels still
remain capable to activate a C1D-directed elimination
mechanism.
Identification of the rescue mechanism
Complete elimination of the cytotoxic C1D(EGFP) from
cells expressing significant but subcritical levels is appar-
ently mediated by the ubiquitin-proteasome system.
Treatment of transfected cultures with the proteasome-
specific inhibitor MG115 results in an increase in the total
number of cells exhibiting extremely high fluorescence
(Fig. 4), and in the overall level of expressed C1D(EGFP).
Quantitative fluorescence microscopy performed by
means of the 'Openlab Measurement Module' points to a
7.5 fold increase of the overall fluorescence in transfected
and inhibitor-treated cultures when compared with trans-
fected cultures in the absence of the inhibitor. The signif-
icant inhibitor-induced increase of expressed C1D(EGFP)
is also shown by Western blotting (Fig. 5). Concomitant-
ly, the fraction of apoptotic cells exhibiting the morphol-
ogies shown in Figure 2 becomes significantly increased
while the fraction of transfectants expressing subcritical
C1D(EGFP) levels remains either unchanged or becomes
reduced (Fig. 4). These results indicate that the effect of
the proteasome-specific inhibitor MG115 is correlated
with higher intracellular levels of C1D(EGFP) and with a
significantly higher fraction of Figure 2-type cells.
The C1D portion of the fusion protein must be considered
to comprise the decisive signal for the proteasome-medi-
ated degradation because the level of ectopically ex-
pressed EGFP is only weakly increased in the presence of
MG115, and MG115-induced degradation is also not a
general characteristics of EGFP-tagged proteins. For in-
stance, the level of the apoptosis-related ZIP-kinase-EGFP
[4] is not significantly increased in the presence of the
MG115 inhibitor (not shown).
Discussion
Inhibition of proteasome-dependent proteolysis favours
apoptotic cell death by increasing gene products consid-
Figure 3
Transfected but non-apoptotic cells. A fraction of cells exhibits weak and rather uniform fluorescence when transfected with
pcDNA3-C1D(EGFP). Cells of this type can be distinguished because exhibiting undisturbed morphology, and much longer
exposure times are required to capture 510 nm fluorescence mode images (2–3 seconds). Left image: phase contrast mode;
right image C1D-EGFP fluorescence (510 nm). Bar represents 10 m.Cancer Cell International 2002, 2 http://www.cancerci.com/content/2/1/12
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ered to be involved in apoptosis signalling [5,6]. Exam-
ples for apoptosis-related gene products upregulated by
proteasome-specific inhibitors include p53 [7–10], p73
[11], p21Cip1(Waf1) [12,13], p27Kip [12,14], and cas-
pases [15,16]. Our results indicate that the C1D protein
must be added to this list of factors.
Physiological levels of the C1D protein are apparently in-
noxious and rather essential for cell viability. However, a
critical overexpression is not tolerated with the conse-
quence of apoptotic cell death [2]. Consistently, C1D ex-
pression is tightly regulated on the transcriptional and on
the posttranscriptional level. The promoter activity is re-
pressed by cis-acting sequences comprised in a LINE-1 up-
stream element [17], and proteasome-mediated
degradation appears to avoid accidental protein levels.
Consequently, a critical C1D(EGFP) level is only achieved
in a relatively small fraction of cells suggestively transfect-
ed with a high number of plasmid copies per cell. In con-
trast, transfectants initially expressing subcritical levels of
the cytotoxic protein have the capability to override the
ectopical overexpression of the cytotoxic protein by acti-
vation of a proteasome-dependent mechanism which de-
grades C1D(EGFP). Consistently, inhibition of the latter
process results in a shift towards higher yields of apoptotic
cells. The concomitant inhibition of the degradation of
Figure 4
MG115 inhibitor-dependent increase of apoptotic cells.
pcDNA3-C1D(EGFP)-transfected cultures were split at 8
hours post transfection and either not supplemented (blank
columns) or supplemented with the proteasome-specific
inhibitor MG115 (10 M) (hatched columns). Microscopical
fluorescence analyses were performed 24 hours post trans-
fection.
Figure 5
Increased levels of ectopically expressed C1D(EGFP) in the
presence of the proteasome-specific inhibitor MG115. Cells
were transfected with pcDNA3-C1D(EGFP). The culture
was split at 8 hours post transfection, and incubation was
continued (16 hours) without (-) or with (+)10 M of the
proteasome-specific inhibitor MG115. Lysates of cell pellets
with identical cell numbers were submitted side by side to
12% SDS-polyacrylamide gelelectrophoresis. Parallel lanes
were either stained (left) or electroblotted to nitrocellulose
which was immuno-stained by means of the monospecific
C1D antibody [1], and 125Iodine-labelled anti rabbit Ig. The
autoradiograph of the blot is shown together with the posi-
tions of prestained marker proteins. The main autoradio-
graphic signal corresponds with the molecular mass of the
C1D(EGFP) fusion protein (43 kDa).Cancer Cell International 2002, 2 http://www.cancerci.com/content/2/1/12
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other apoptosis-favouring proteins [7–16] may contribute
to this higher yield of apoptotic cells.
Conclusions
Survival of tumor cells is in all or in part due to their ina-
bility to activate the programmed cell death [18]. Accord-
ingly, factors with the characteristics of C1D are of interest
with respect to the elimination of nondesired cells, e.g. tu-
mor cells. It is concluded that the yield of apoptotic cells
is significantly increased by vector-dependent C1D ex-
pression in combination with inhibitors of the proteas-
ome-dependent degradation of the C1D gene product.
Materials and Methods
EGFP fusion and expression constructs
The preparation of C1D(EGFP) expression constructs are
described elsewhere in detail [2]. Briefly, the PCR-ampli-
fied sequence encoding the murine C1D protein
(X95591) was fused with the sequence encoding EGFP
(Clontech) in the pBluescript KS+ vector (Stratagene). The
fused C1D(EGFP) sequence was excised with suitable re-
strictases and recloned either in the CMV promoter-driven
pcDNA3 vector (Invitrogen) or in the SV40 promoter-
driven pJ3 vector [19]. The sequence encoding the ZIP-
kinase [4] was assembled from coding fragments present
on ESTs (IMAG 457285, IMAG 386126) which were re-
ceived from the 'Ressourcenzentrum im Deutschen Hu-
mangenomprojekt'. Fusion with the EGFP-encoding
sequence and recloning in the pcDNA3 vector was per-
formed as described for the C1D sequence. For controls
the EGFP-encoding sequence was recloned in the pcDNA3
vector.
Cell cultures and transient transfections
Ehrlich ascites tumor (EAT) cells grown as described else-
where in detail [20] were transfected with Qia-tip (Qia-
gen) purified plasmids by electroporation using the
Biorad Gene Pulser II (cell density 107 per ml, electrode
distance D = 4 mm, 366V / 950 F). For detection of pro-
teasome inhibitor effects the medium of exponentially
growing transfected and non-transfected cells was supple-
mented with MG115 (benzyloxycarbonyl-leu-leu-norvali-
nal, Calbiochem) to obtain the final concentrations
mentioned in the legends of Figures 4 and 5.
Western blot
EAT cells were lysed in 2 sample buffer containing 5% -
mercapto ethanol at 95C. Aliquots corresponding to a
defined number of cells and prestained marker proteins
were submitted to SDS polyacrylamide (12% w / v) gel
electrophoresis. Gel lanes were electro-blotted to nitrocel-
lulose membranes, blocked (PBS / 1% BSA), and probed
with C1D antibodies preadsorbed at recombinant murine
C1D protein [1]. The second antibody was 125Iodine-la-
beled anti rabbit Ig (Amersham). Blots were exposed to
Kodak X-Omat film and images were captured by means
of an electronic camera (Herolab).
Microscopy
The Openlab imaging sytem (Improvision, Warwick, UK)
was used to capture images. Cells were collected, washed
with phosphate-buffered saline (PBS), counterstained
with Hoechst 33342 (0.1 g per ml), resuspended in
Hanks' balanced salt solution (HBSS), mounted on glass
slides and inspected by microscopy. The 'Measurements
Module' was used to measure mean fluorescence intensi-
ties per cell in regions of interest (ROIs).
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